Mattress Firm-funded trials seek to shrink tumors in advanced casesContinue reading
Author Archive: AZBio
Stand Up To Cancer Launches “Catalyst,” a New Research Program Supported by Industry
Collaborative program sponsored by Merck, Bristol-Myers Squibb and Genentech will fund efforts to drive cancer research
La Pitié Hospital, Paris, has implanted more SynCardia Total Artificial Hearts than any other medical center in the world.
World’s Leading Artificial Heart Center, La Pitié Hospital, Paris, Celebrates 30 Years and 249 Implants of the SynCardia Total Artificial HeartContinue reading
HTG Molecular Diagnostics Expands Distribution into Israel, Spain and Portugal
HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and PortugalContinue reading
Syntactx Partners with arivis to Decrease Time for Document Management in Medical Device Trials
Syntactx Replaces Manual, Paper-based System with arivis Clireo eTMFContinue reading
AZBio Watch List for April 11 2016
AZBio Members are encouraged to share thoughts on these bills and others with the Government Affairs Committee. Email AZBioContinue reading
Positive Impact: Arizona Angel Investor Tax Credit
Arizona’s Angel Investment Tax Credit program has proven to be extremely successful with a track record of more than a 2.3 to 1 return on investment. More than $420 million in financing is attributable to this program, in addition to the $62 million raised through the credits for investments. That combined ROI is 1,750% making the total economic impact to the Arizona’s economy an estimated $1.3 billion. This program is an essential instrument in Arizona’s economic development tool box and we cannot afford to lose it.
Continue reading
TGen Tackles Valley Fever, One Canine at a Time
Volunteers are sought to discover how our four-legged friends could offer insight into this debilitating disease caused by Arizona dustContinue reading
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that, if untreated, progresses to colorectal cancer in almost all cases. The trial has enrolled 166 patients at 21 research institutes in the United States, Canada and Europe.Continue reading
TGen and Mayo Clinic scientists issue report in Cell on advances in basal cell carcinoma treatment
Drugs target the Hedgehog cellular pathway to attack the nation’s most common skin cancer, affecting nearly 2.8 million Americans each yearContinue reading